|Day Low/High||15.01 / 15.49|
|52 Wk Low/High||4.26 / 23.61|
A look at Jim Cramer's thoughts on companies of interest to 'Mad Money' viewers.
Investors keep coming up with reasons to hate the bull market.
In trading on Monday, shares of Cara Therapeutics Inc crossed below their 200 day moving average of $13.51, changing hands as low as $12.31 per share. Cara Therapeutics Inc shares are currently trading down about 9.3% on the day.
In recent trading, shares of Cara Therapeutics Inc have crossed above the average analyst 12-month target price of $25.75, changing hands for $26.42/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
It would be better from a trading standpoint for this market to sell off with some vigor.
Phase 3 safety extension trial underway
Jim Cramer focuses in on AK Steel Holdings, Cara Therapeutics, Nucor, and Smart and Final Stores.
The real exaggeration, says Jim Cramer, may be the influence of the bond market. But you can't ignore bonds, either.
Go inside Jim Cramer's Apple call.
Jim Cramer is bullish on Charles Schwab, Essent Group, Cara Therapeutics, and MGM Growth Properties.
Although a cannabis ETF launched in April, investors are still likely to find more value in buying individual stocks in the sector, according to traders.
Jim Cramer is bullish on Foot Locker, Cara Therapeutics, National Grid, and Home Depot.
Jim Cramer says that when it comes to alarming negativity and ridiculous exuberance, both extremes are wrong; investors need to get real.
Jim Cramer is bullish on Six Flags and Cara Therapeutics, but he's bearish on General Motors and Pandora.
Jim Cramer says he's amazed that stocks -- and gold, even -- are just yawning at Trump's move to fire FBI Director Comey.
Jim Cramer says he respects Buffett's judgment. Cramer's also bullish on some airline stocks.
Jim Cramer says a rally on French election results is fine, but don't forget great U.S. corporate earnings and merger activity.
- I.V. CR845 statistically equivalent to placebo across all measures of respiratory safety -
Incyte has been doing great, locking in deals with Bristol-Myers and Merck. It's worth a lot more in a takeover situation, Cramer said.
Jim Cramer stresses discipline here because, he says, a frothy market can quickly turn on investors.